Time To ACT (TTA) | AQSE:TTA

Time To ACT shares remain volatile and lightly traded after the microcap engineering group completed a GBP500,000 buyout of MTE Heat Treatment. With losses widening and cash tight, investors are weighing the growth story against clear balance-sheet and liquidity risks.

What happened

Time To ACT plc, the small-cap engineering and cleantech group quoted on the Aquis Stock Exchange (AQSE) Growth Market under the ticker TTA, has been on investors' radar after completing its Acquisition of MTE Heat Treatment Limited, a West Yorkshire thermal processing Business bought out of administration for GBP500,000.

The deal, confirmed via a Completion of Acquisition RNS on 19 May 2026, was framed by management as a bolt-on that adds thermal engineering capability to Time To ACT's existing Diffusion Alloys coatings business. It landed at a delicate moment for a genuinely tiny, thinly traded stock: Market Capitalisation of only a few million pounds, with daily volumes often just a few thousand shares and a bid-offer spread that has at times run to over 20% of the mid-price.

That illiquidity matters. On such thin volumes, single trades can swing the quoted price sharply either way, so any single day's percentage move likely says more about a thin order book than about the underlying business. Combined with a recent CFO departure and a widening interim loss, though, there is plenty for shareholders to weigh as they judge whether the growth strategy is working.

Latest company news

The MTE Heat Treatment acquisition completed on 19 May 2026. Time To ACT paid GBP500,000 — roughly GBP390,000 for plant and equipment and GBP110,000 for the trade and business — with GBP286,000 of equipment finance provided by a pension fund belonging to director and Shareholder Chris Heminway, and the balance funded by the company.

MTE reported 2025 turnover of GBP2.834 million, down 21% from GBP3.562 million the prior year, before going into administration. Time To ACT has guided to first-year annualised sales of around GBP3.0 million under its ownership with positive EBITDA targeted, and says the deal broadens its Manufacturing footprint, adds boronising capability, and creates cross-selling potential with Diffusion Alloys' gear and industrial parts customers.

The acquisition followed a GBP415,000 Equity fundraise completed on 2 April 2026 at 6 pence per share — well below where the stock now trades. Three days after completion, the company issued a hydrogen update confirming Diffusion Alloys remains a supply-chain partner to Johnson Matthey's Catalyst Technologies on the HPP1 blue hydrogen project, targeting a Final Investment Decision in the second half of 2026.

On leadership, CFO Gary Wallace is stepping down effective 17 July 2026, following an earlier non-executive director change on 30 April 2026. The company has also run investor engagement events, including a Yellowstone Advisory private investor evening around 24 June 2026, given limited Sell-Side coverage typical of AQSE-listed names.

Financial position

Time To ACT's most recent interim results, covering the six months to 30 September 2025 and released 30 December 2025, showed Revenue of GBP732,370, down sharply from GBP1,665,199 a year earlier, largely due to the absence of a roughly GBP750,000 'Large Parts' contract that had boosted the prior comparative period.

Gross profit was GBP351,555, a 48% margin, but the operating loss widened to GBP650,484 from GBP137,560, and the net loss deepened to GBP683,224 from GBP169,494. Cash stood at GBP299,227 at the half-year end, a level the company said would improve materially following a GBP1.012 million raw materials sale, of which GBP540,000 was received in November 2025.

Trailing twelve-month figures compiled by third-party data providers show revenue of around GBP2.28 million, up roughly 21% year-on-year, alongside a net loss near GBP964,000 — improving top-line trends, but still loss-making overall.

Funding has come mainly through small, dilutive equity placings, including the GBP415,000 raise at 6p in April 2026, plus director-backed equipment finance for the MTE deal. With around 21.99 million shares in issue and a market capitalisation of only a few million pounds, Time To ACT has limited financial firepower, so further fundraisings and dilution cannot be ruled out.

Why the shares may be under pressure

There is no clear evidence the MTE acquisition announcement alone drove any specific sharp share price move; on AQSE-quoted micro-caps like Time To ACT, small trade sizes and wide spreads routinely produce large percentage swings that reflect thin liquidity rather than a shift in sentiment.

That said, several verifiable factors help explain investor caution. Widening interim operating and net losses, against falling first-half revenue, point to execution risk as the company works to restore growth. Reliance on small, discounted equity placings raises dilution concerns. The CFO's departure in July 2026 adds management-transition risk during the MTE integration. And MTE itself was acquired out of administration with declining recent turnover, meaning the turnaround carries genuine integration risk rather than being a straightforward bolt-on of a healthy business.

More broadly, a thin free float — reportedly around three-quarters of shares held off-market — limits active buyers and sellers, amplifying Volatility around any news flow.

Bull case

Supporters point to the MTE deal's low headline cost relative to the capability it adds — plant, trade relationships and roughly GBP3 million of annualised revenue potential for GBP500,000 — with management projecting positive EBITDA in year one.

The combination with Diffusion Alloys' coating and thermal engineering expertise could create genuine cross-selling opportunities and a broader, less commoditised offering to industrial customers, per management commentary.

Longer term, continued involvement in the HPP1 blue hydrogen project alongside Johnson Matthey's Catalyst Technologies offers a potential reference win if the project reaches a positive Final Investment Decision in H2 2026, positioning Time To ACT within the UK energy-transition Supply chain alongside its GreenSpur renewable generator technology.

Bear case

The clearest risk is financial: Time To ACT is loss-making, holds a small cash balance, and has repeatedly turned to dilutive equity raises, leaving shareholders exposed to further dilution if performance does not improve.

Integration risk is real. MTE went into administration with turnover down 21% year-on-year before the sale, and turning a distressed asset into a reliable, profitable contributor is rarely straightforward for an acquirer of Time To ACT's limited scale.

The HPP1 hydrogen opportunity is not guaranteed — the company itself flagged delays across UK government-backed hydrogen projects, and the Final Investment Decision timeline could slip further.

Finally, extremely thin liquidity and a wide bid-offer spread mean investors may struggle to trade in size without materially moving the price, and the quoted share price can be volatile and potentially unrepresentative of Fair Value at any given moment.

What investors should watch next

Full-year results and updated trading commentary, expected around late September 2026 based on the company's reporting calendar, should show whether MTE is tracking toward its targeted GBP3 million annualised sales and positive EBITDA.

Progress on the HPP1 blue hydrogen project's Final Investment Decision, expected in H2 2026, is a key catalyst given management's description of the project as financially significant.

The appointment of a permanent CFO to succeed Gary Wallace, who departs on 17 July 2026, will signal management stability during the MTE integration. Investors should also watch for further equity fundraising announcements, order intake, and Margin trends across both Diffusion Alloys and MTE.

Conclusion / outlook

(AQSE:TTA) Time To ACT remains a high-risk, early-stage growth story rather than an established, cash-generative industrial group. The GBP500,000 MTE Heat Treatment acquisition adds scale at a modest headline price, and the hydrogen supply-chain relationship offers a longer-term catalyst, but both sit alongside widening losses, a small cash position and a history of dilutive fundraising.

For the shares to re-rate sustainably, investors will likely want evidence that MTE is integrating profitably, that losses are narrowing, and that management has stabilised following the CFO transition. Given the stock's extremely thin liquidity, near-term price moves should be read with caution, and anyone considering Time To ACT stock should weigh the speculative nature of a pre-profit, small-cap AQSE name against their own risk tolerance. This article is for information purposes only and does not constitute personalised financial advice.